RewordedRisk Factors
Although our share repurchase program is intended to enhance long-term shareholder value, short-term stock price fluctuations could reduce the program’s effectiveness Refer to Note 7, Earnings per Share, to the Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K for additional information. effectiveness.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Before a new medical device, or a new use of an existing product product, can be marketed in the United States, it must first receive either premarket clearance under Section 510(k) of the U.S. FDCA, a grant of a request for de novo classification or a premarket approval, or PMA, from the FDA, unless an exemption applies.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although we did not have any customers that represented more than 10% of our consolidated revenues in fiscal 2025, a A material portion of sales in our Plasma segment come from (and we anticipate will continue to come from) a limited number of customers.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In fiscal 2025, our ten largest customers 2026, one Plasma customer accounted for approximately 42% 13% of our total net revenues.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are continuing to monitor the situation situations in Ukraine Ukraine, Iran and other parts of the Middle East and globally as well as to assess its potential impact on our business.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
We are required to comply with increasingly complex and changing legal and regulatory requirements that govern the collection, use, storage, security, transfer, disclosure and other processing of personal data in the United States and in other countries, including, but not limited to, HIPAA, HITECH, the California Consumer Privacy Act, or CCPA, Act (“CCPA), the California Privacy Rights Act, and the EU’s General Data Protection Regulation, or GDPR. Regulation (“GDPR”).
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In May 2024, the Company issued $700.0 million aggregate principal amount of indebtedness under the Company’s convertible notes due 2029, or 2029 Notes, (“2029 Notes”), and used $230.0 million of the proceeds to repay the entirety of the previously outstanding balance under the Company’s senior unsecured revolving credit facility and $185.5 million of the proceeds to repurchase $200.0 million in aggregate principal amount of the Company’s convertible senior notes due 2026, or 2026 Notes. (“2026 Notes”).
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
In Further, in addition to fluctuations in foreign exchange rates, discussed below, our business in markets outside the United States is subject to changing political, social and geopolitical conditions, such as tensions between China and Taiwan and the wars in Ukraine Ukraine, Iran and other parts of the Middle East, including any political instability resulting from war, terrorism, insurrections and civil unrest, and changing economic conditions in these markets, such as inflation, deflation, interest rate volatility and credit availability.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedRisk Factors
A default under an the Indenture or the fundamental change itself could also lead to a default under agreements governing our other indebtedness, including our 2024 Revised Credit Facilities and the other Notes, Facilities, which may result in that other indebtedness becoming immediately payable in full.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
On January 9, 2026, we acquired all of the outstanding equity interests of Vivasure for a net purchase price of $164.4 million. The net purchase price included $60.2 million paid in cash at closing, net of $0.4 million cash acquired and after giving effect to the value of certain prior investments and loans we made to Vivasure, as well as other customary closing adjustments, and the fair value of contingent consideration of $20.7 million. The contingent consideration is based on sales growth over the three years following the completion of the acquisition and the achievement of certain other milestones, and is also subject to adjustments based on the value of certain prior investments and loans. The Company financed this transaction through available cash on hand.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Vivasure is a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure’s PerQseal Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a premarket approval, or PMA, application to the FDA for the PerQseal Elite arterial closure system and received CE Mark in Europe for both arterial and venous indications. The addition of Vivasure expands our Hospital business unit portfolio in the interventional cardiology market and will be included in the Hospital reportable segment.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
On March 2, 2026, we repaid in full at maturity our outstanding 2026 Notes for an aggregate amount of $300.0 million in cash, representing the outstanding principal amount of the 2026 Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the 2026 Notes prior to the close of business on the second scheduled trading day immediately preceding the maturity date. The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
•Expansion in the availability of plasma-derived therapies across new geographic markets also increases demand for plasma.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Net revenues decreased 2.0% during fiscal 2026 as compared with fiscal 2025. The decrease was driven by prior year portfolio transitions in Plasma and Blood Center—including the previously announced customer transition of CSL Plasma and the divestiture of the Whole Blood product line—that together represented approximately $153 million of nonrecurring fiscal 2025 revenue, partially offset by an increase in Hospital, primarily attributable to the Hemostasis Management and Transfusion Management product lines within the Blood Management Technologies franchise.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
(2) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
(3) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Fiscal Year 2026 2025 Reported growth Currency impact Constant currency growth(1) (Dollars in Thousands) Gross profit $ 787,586 $ 748,958 5.2% 1.3% 3.9% % of net revenues 59.0 % 55.0 %
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Interest and other expenses, net increased 194.5% during fiscal 2026 as compared with fiscal 2025. The increase was primarily driven by gains recognized in the first quarter of fiscal 2025 on the repurchase of $200.0 million of aggregate principal of our 2026 Notes. For further discussion on the 2026 Notes, refer to Note 12, Notes Payable and Long-Term Debt within the accompanying consolidated financial statements for further information.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
(1) Availability under our revolving credit facilities is reduced by eligible outstanding letters of credit allowable of $1.3 million as of March 28, 2026 and March 29, 2025, respectively.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
On March 2, 2026, we repaid in full at maturity our 2026 Notes for an aggregate amount of $300.0 million in cash, representing the outstanding principal amount of the 2026 Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the 2026 Notes prior to maturity. The capped call transactions entered into in connection with the issuance of the 2026 Notes expired in accordance with their terms upon the maturity of the 2026 Notes.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
AddedMD&A
Goodwill is tested for impairment at least annually as of the first day of the fourth quarter in fiscal 2026, or more frequently if events or changes in circumstances indicate potential goodwill impairment. The test is performed at the reporting unit level by comparing the estimated fair value of each reporting unit to its carrying value, including goodwill.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RemovedMD&A
On December 3, 2024, we announced that we entered into a definitive agreement to sell our Whole Blood product line and related assets within our Blood Center business unit to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include our complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with our manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at our manufacturing facility in Tijuana, Mexico. On January 13, 2025, we completed the transaction with GVS for total cash consideration of up to $65.8 million, which includes $43.3 million upfront and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones. As part of the transaction, we divested $26.4 million of inventory, $7.8 million of property, plant and equipment and $6.4 million of goodwill allocated based on fair value previously recorded in the Blood Center reportable segment in the Consolidated Balance Sheets. We recognized a gain on sale related to the divestiture which was not material.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
In April 2025, our Board of Directors approved a new share repurchase authorization of up to $500.0 million of Haemonetics common stock over the next three years. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. The timing and amounts of activity under the repurchase program will be at management’s discretion. In addition to this share repurchase activity, our capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate our long-term growth plans.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
On May 28, 2024, we issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between us and U.S. Bank Trust Company, National
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, of which $230.0 million was used to repay the entirety of the previously outstanding balance on the Company’s senior unsecured revolving credit facility, $185.5 million was used to repurchase $200.0 million in aggregate principal amount of the Company’s 0% convertible senior notes due 2026 and $88.2 million was used to complete capped call transactions, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
On April 1, 2024, we completed our acquisition of Attune Medica for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. We financed the acquisition through a combination of cash on hand and borrowings under our senior unsecured revolving credit facility.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The addition of our Esophageal Protection product line through this acquisition expands our Hospital business unit’s presence in electrophysiology and complements our Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
On October 10, 2023, we entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, we agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, we completed our acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. We financed the acquisition through a combination of cash on hand and borrowings under our senior unsecured revolving credit facility.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for TAVR procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (“FFR”) and diastolic pressure ratio (“dPR”) to aid clinicians in the diagnosis and treatment of patients with coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
During the fourth quarter of fiscal 2025, we incurred $0.6 million of restructuring related costs related to the first action under this initiative, which were approved by our Board of Directors in January 2025. Total cumulative charges under this initiative are $0.6 million as of March 29, 2025.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
of care around the world. The HAS-100 and HAS-300 are currently commercialized in China, where there has been a significant reduction in government reimbursement for testing and enforcement of strict pricing limitations, both of which constrain the growth potential in the market.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth(1) Revenues by business unit(2) Plasma(3) 535,431 569,535 (6.0)% (0.1)% (5.9)% Apheresis 213,134 211,173 0.9% (1.5)% 2.4% Whole Blood 47,990 72,058 (33.4)% (0.1)% (33.3)% Blood Center 261,124 283,231 (7.8)% (1.1)% (6.7)% Interventional Technologies(4) 255,019 174,285 46.3% (0.6)% 46.9% Blood Management Technologies(5) 309,250 282,004 9.7% (0.2)% 9.9% Hospital 564,269 456,289 23.7% (0.3)% 24.0% Total net revenues $ 1,360,824 $ 1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency. See “Management’s Use of Non-GAAP Measures.” (2) Beginning in fiscal 2025, we integrated service revenue within our three business units. Prior periods were conformed to current presentation. (3) Plasma revenue includes CSL U.S. disposables revenue of $12.3 million and $99.8 million in the fourth quarter and full year of fiscal year 2025, respectively, as compared to $36.3 million and $154.53 million in the fourth quarter and full year of fiscal 2024, respectively. (4) Interventional Technologies includes Vascular Closure, Sensor -Guided Technologies and Esophageal Protection product lines of the Hospital business. (5) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RemovedMD&A
Fiscal Year (In thousands) 2025 2024 % Increase/(Decrease) Research and development $ 62,722 $ 54,435 15.2% % of net revenues 4.6 % 4.2 % Selling, general and administrative $ 436,789 $ 431,780 1.2% % of net revenues 32.1 % 33.0 % Amortization of acquired intangible assets $ 48,261 $ 32,031 50.7% % of net revenues 3.5 % 2.4 % Remeasurement of contingent consideration $ (23,022) $ — n/m % of net revenues (1.7) % — % Gains on divestiture and sale of assets $ — $ (2,000) n/m % of net revenues — % (0.2) % Impairment of intangible assets $ 2,391 $ 10,419 (77.1)% % of net revenues 0.2 % 0.8 % Total operating expenses $ 527,141 $ 526,665 0.1% % of net revenues 38.7 % 40.2 %
Read it in 10-K May 21, 2025 at sec.govopen_in_new
RewordedMD&A
March 28, 2026 March 29, 2025 (Dollars in thousands) March 29, March 30, 2025 2024 Thousands) Cash and cash equivalents $ 245,440 $ 306,763 Availability under revolving credit facilities(1) $ 178,800 448,697 $ 748,697 Working capital $ 552,280 $ 356,862 $ 468,520 Current ratio 3.0 1.6 2.6 Net debt position(1) position(2) $ (979,140) $ (918,025) $ (628,993) Days sales outstanding ("DSO") 56 55 54 Inventory turnover 1.5 1.4 1.7 (1)Net debt position is the sum of cash and cash equivalents less total debt.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Our effective reported tax rate for the year ended March 29, 2025 28, 2026 is lower higher than our effective reported tax rate of 22.6% 20.9% for fiscal 2024, 2025, primarily due to the favorable impact of contingent consideration remeasurement and tax benefits attributable to the expiration of the statute of limitations associated with uncertain tax position reserves, positions reserves and contingent consideration benefits recorded in FY25, partially offset by the impact of the jurisdictional mix of earnings.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Fiscal Year (In thousands) 2025 2024 Reported growth Currency impact Constant currency growth (1) United States $ 1,010,918 $970,007 4.2% —% 4.2% International 349,906 339,048 3.2% (1.5)% 4.7% Net revenues $ 1,360,824 $1,309,055 4.0% (0.3)% 4.3% (1) Constant currency growth, a non-GAAP financial measure, measures the change in revenue between the current and prior year periods using a constant currency.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Operating activities $ 293,221 $ 181,725 $ 181,751 Investing activities (179,547) (161,895) (322,389) Financing activities (178,460) 108,818 38,157 Effect of exchange rate changes on cash and cash equivalents(1) 3,463 (685) (3,185) Net change in cash and cash equivalents $ (61,323) $ 127,963 $ (105,666) (1) The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease in Blood Center’s reported revenue was primarily driven by declines in the divestiture of our Whole Blood business, which was divested product line in the fourth quarter of fiscal 2025. January 2025, partially offset by favorable product mix and higher volume.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
Without Plasma revenue decreased by 2.0% on an as reported basis and decreased by 2.7% without the effect of foreign exchange, Plasma revenue decreased 5.9% exchange during fiscal 2025 2026 as compared with fiscal 2024. 2025.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
GAAP”), In addition to financial measures in accordance with accounting principles generally accepted in the United States of America (“GAAP”), management uses non-GAAP financial measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
In the fourth quarter of fiscal 2025, we We recognized a benefit of $20.3 $1.9 million and $23.0 million during fiscal 2026 and fiscal 2025, respectively, related to the remeasurement of acquisition related acquisition-related contingent consideration.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
RewordedMD&A
During fiscal 2025, Dollar, 26.4% and 25.7% of our sales in fiscal 2026 and fiscal 2025, respectively, were generated outside the U.S., generally in foreign currencies, yet our reporting currency is the U.S. currencies.
Read it in 10-K May 20, 2026 at sec.govopen_in_new
Quiet changesMD&A
As a result, there are relatively few customers for our Plasma products, especially in the U.S. where approximately over two-thirds of the world’s source plasma is collected and only a few customers provide the majority of our Plasma revenue.
Read it in 10-K May 20, 2026 at sec.govopen_in_new